Summary
4-Demethoxydaunorubicin (4-DMDR) and its major metabolite 4-demethoxy-13-hydroxydaunorubicin (4-DMDRol) were investigated for their cytotoxicity and mode of action against human leukemic cells. The drug and its metabolite appeared to be equally potent as both inhibitors of cell proliferation and inducers of DNA double-strand breaks in the OCI AML-3 cell line and cells derived directly from patients with acute myeloid leukemia (AML). This suggests that 4-DMDRol plays an important role in the antileukemic activity of 4-DMDR.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Arcamone F, Bernardi L, Giardino P, Patelli B, DiMarco A, Casazza AM, Pratesi G, Reggiani P (1976) Synthesis and antitumor activity of 4-demethoxydaunorubicin, 4-demethoxy-7,9-diepidaunorubicin, and their β-anomers. Cancer Treat Rep 60: 829
Belvedere G, Suarato A, Geroni C, Giuliani FC, D’Incalci M (1990) Comparison of intracellular drug retention, DNA damage and cytotoxicity of derivatives of doxorubicin and daunorobucin in a human colon adenocarcinoma cell line (LoVo). Biochem Pharmacol 38: 3713–3721 (1989)
Capranico G, Soranzo C, Zunino F (1986) Single-strand DNA breaks induced by chromophore-modified anthracyclines in P388 leukemia cells. Cancer Res 46: 5499
Griffin JD, Lowenberg B (1986) Clonogenic cells in acute myeloblastic leukemia. Blood 68: 1185
Harousseau JL, Hurteloup P, Reiffers J, Rigal-Huguet F, Hayat M, Dufour P, Le Prise PY, Monconduit M, Jaubert J, Carcassonne Y (1987) Idarubicin in the treatment of relapsed or refractory acute myeloid leukemia. Cancer Treat Rep 71: 991
Kohn KW, Ewig RAG, Erickson LC, Zwelling LA (1981) Measurement of strand breaks and cross-links by alkaline elution. In: Friedberg EC, Hanawalt PC (eds) DNA repair, vol 1, part B, Marcel Dekker, New York, p 379
Lowenthal RM, Chesterman CN, Griffiths JD, Manoharan A, Harris MG, Herrmann RP, Rooney KF, Rozenberg MC, Salem HHH, Wolf MM, Woodruff RE (1987) Oral idarubicin as single-agent treatment of acute nonlymphocytic leukemia in poor-risk patients. Cancer Treat Rep 71:
Madon E, Grazia G, DeBernardi B, Comelli A, Carli M, Sainati L, Paolucci G, Canino R, Colella R, Bagnulo S, Di Pietro N (1987) Phase II study of idarubicin administered i.v. to pediatric patients with acute lymphoblastic leukemia. Cancer Treat Rep 71: 855
Pike BL, Robinson WA (1970) Human bone marrow colony growth in agar gel. J Cell Physiol 76: 77
Speth PAJ, Loo FAJ van de, Linssen PCM, Wessels HMC, Haanen C (1986) Plasma and human leukemic cell pharmacokinetics of oral and intravenous 4-demethoxydaunomycin. Clin Pharmacol Ther 40: 643
Zanette L, Zucchetti M, Freschi A, Erranti D, Tirelli U, D’Incalci M (1990) Pharmacokinetics of 4-demethoxydaunorubicin in cancer patients. Cancer Chemother Pharmacol 25: 445–448
Author information
Authors and Affiliations
Additional information
Supported by Fondazione Tettamanti
Rights and permissions
About this article
Cite this article
Limonta, M., Biondi, A., Giudici, G. et al. Cytotoxicity and DNA damage caused by 4-demethoxydaunorubicin and its metabolite 4-demethoxy-13-hydroxydaunorubicin in human acute myeloid leukemia cells. Cancer Chemother Pharmacol 26, 340–342 (1990). https://doi.org/10.1007/BF02897289
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02897289